Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 366-373

  Kimball, A B ^a   Schenfeld, J ^b   Accortt, N A ^b   Anthony, M S ^b   Rothman, K J ^c   Pariser, D ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c RTI INTERNATIONAL   (United States)

^d Virginia Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PSORIASIS; UNITED STATES;

EID: 84894236899     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12744     Document Type: Review

References (21)

1. Gelfand JM, Stern RS, Nijsten T, et al,. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52: 23-6.
2. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2008; 60: 218-24.
3. Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
4. Menter A, Gottlieb A, Feldman S, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Am Acad Dermatol 2008; 58: 826-50.
5. National Institute of Health. Psoriasis. Available at: http://www.nlm.nih.gov/medlineplus/psoriasis.html (accessed on 20 November 2013).
6. National Psoriasis Foundation. Treating Psoriasis. Available at: http://www.psoriasis.org (accessed on 20 November 2013).
7. Greaves M, Weinstein G, Wood L,. Treatment of psoriasis. N Engl J Med 1995; 332: 581-9.
8. Bahner J, Cao L, Korman N,. Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol 2009; 2: 111-28.
9. Boffetta P, Gridley G, Lindelof B,. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-7.
10. Gelfand J, Berlin J, Voorhees A, et al,. Lymphoma rates are low but increased in patients with psoriasis. Arch Dermatol 2003; 139: 1425-9.
11. Gelfand J, Shin D, Neimann A, et al,. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-201.
12. Margolis D, Bilker W, Hennessy S, et al,. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778-83.
13. Paul C, Ho V, McGeown C, et al,. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-16.
14. Patel R, Clark L, Lebwohl M, et al,. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-17.
15. Gottlieb A, Chao G, Dann F,. Psoriasis comorbidities. J Derm Treat 2008; 19: 5-21.
16. Eide MJ, Krajenta R, Johnson D, et al,. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol 2010; 171: 123-8.
17. Toh S, Li L, Harrold LR, et al,. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristic? Pharmacoepidemiol Drug Saf 2012; 21: 524-34.
18. Curtis J, Xie F, Chen L, et al,. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res 2012; 64: 1480-9.
19. Grijalva CG, Chen L, Delzell E, et al,. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
20. Hochberg MC, Lebwohl MG, Plevy SE, et al,. The benefit/risk profile of tnf-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-36.
21. Le Blay P, Mouterde G, Barnetche T, et al,. Risk of malignancy including non-melanoma skin cancers with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clinical Exp Rheumatol 2012; 30: 756-64.